To confirm that fruquintinib exerts its inhibitory effects by modulating the TGFβ/SMAD2-3 signaling axis, we treated CRC cells with fruquintinib in conjunction with the TGF-β receptor agonist KRFK TFA. Here, TGFB1 is linked to colorectal carcinoma.